David G. Miller, RPh, on the Drug Quality and Security Act

Published Online: Tuesday, November 12, 2013
Follow Pharmacy_Times:
In this video, David G. Miller, RPh, executive vice president and CEO of the International Academy of Compounding Pharmacists (IACP), discusses H.R. 3204, the Drug Quality and Security Act, which passed the House of Representatives on September 25, 2013. Miller explains that IACP opposes the bill because it reaffirms section 503A of the Federal Food, Drug, and Cosmetic Act rather than fixing its problems. This video was recorded at the National Community Pharmacists Association 115th Annual Convention in Orlando.

Related Articles
To provide further guidance on issues concerning drug compounding, the FDA today announced that experts in pharmacy, pharmaceutical compounding and manufacturing, medicine, and pharmaceutical regulation will comprise the Pharmacy Compounding Advisory Committee.
Although the proposed USP General Chapter <800> is not anticipated to take effect for at least the next 2 years, an expert panel described how pharmacists can start preparing for the new standards in handling hazardous drugs.
The key to encouraging patient proactivity at Burmans Pharmacy is to stress medication adherence, director of compounding Vince Canzanese, RPh, explains.
For Vince Canzanese, RPh, director of compounding for Burmans Pharmacy, building patient trust relies on a key factor: not allowing a mailman to become the pharmacist.
Latest Issues
$auto_registration$